Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Nivolumab in Recurrent and/or Metastatic Salivary Gland Carcinoma
2016-001794-32Phase 2Active
- Sponsor
- Unicancer
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in salivary gland cancer (SGC), sponsored by Unicancer. Primary endpoint: Non-progression rate at 6 months. Started Nov 2016; status: active.
02
Drugs
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on 2016-001794-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001794-32.